Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BIIB
BIIB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BIIB News
Biogen's Litifilimab Shows Positive Results in Cutaneous Lupus Study
2d ago
Newsfilter
Alteogen Enters $579 Million Licensing Deal with Biogen
4d ago
NASDAQ.COM
Alteogen and Biogen Sign Exclusive License Agreement
5d ago
seekingalpha
ALTEOGEN INC - BIOGEN HAS THE OPTION TO DEVELOP A THIRD PRODUCT UNDER THE AGREEMENT
5d ago
moomoo
ALTEOGEN SIGNS LICENSE DEAL WITH BIOGEN FOR HYBROZYME™-BASED SUBCUTANEOUS BIOLOGICS DEVELOPMENT AND MARKETING
5d ago
moomoo
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment
Mar 20 2026
PRnewswire
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment
Mar 20 2026
Newsfilter
UK to Reassess Alzheimer’s Drugs Exclusion from NHS
Mar 20 2026
seekingalpha
Johnson Fistel Investigates Executive Liability for Multiple Companies
Mar 12 2026
Globenewswire
Biogen Unveils New Research Data on Spinal Muscular Atrophy
Mar 05 2026
Newsfilter
Stoke and Biogen Release Zorevunersen Study Data
Mar 05 2026
NASDAQ.COM
Zorevunersen Shows Promise for Dravet Syndrome Treatment
Mar 04 2026
Newsfilter
Market Dynamics and Investment Opportunities Analysis
Feb 20 2026
CNBC
Biogen Elects New Chair of the Board
Feb 11 2026
Newsfilter
Biogen Elects Dr. Maria C. Freire as New Chair of the Board
Feb 11 2026
Yahoo Finance
Biogen Reports Q4 and Full Year 2025 Earnings Exceeding Expectations
Feb 09 2026
Newsfilter
Show More News
